Jupiter Neurosciences (JUNS) Short Interest Ratio & Short Volume

Short interest is the volume of Jupiter Neurosciences shares that have been sold short but have not yet been covered or closed out. As of August 31st, investors have sold 187,600 shares of JUNS short. 1.28% of Jupiter Neurosciences' shares are currently sold short. Learn More on Jupiter Neurosciences' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.28% of Jupiter Neurosciences' floating shares are currently sold short.

Jupiter Neurosciences saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 187,600 shares, a decline of 8.2% from the previous total of 204,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Jupiter Neurosciences currently has issued a total of 34,830,000 shares. Some of Jupiter Neurosciences' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Jupiter Neurosciences currently has a public float of 14,610,000 shares.

1.28% of Jupiter Neurosciences' shares are currently sold short. Here is how the short interest of companies in the industry of "med - drugs" compare to Jupiter Neurosciences: China SXT Pharmaceuticals, Inc. (0.04%), Achieve Life Sciences, Inc. (10.45%), Avalo Therapeutics, Inc. (0.53%), Wellgistics Health, Inc. (7.00%), Profound Medical (2.33%), Protara Therapeutics, Inc. (8.46%), Corbus Pharmaceuticals Holdings, Inc. (10.83%), Avita Medical Inc. (18.76%), Pyxis Oncology, Inc. (9.81%), Cassava Sciences, Inc. (13.00%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($73.23 billion), Invesco QQQ ($29.52 billion), iShares Russell 2000 ETF ($20.82 billion), iShares 20+ Year Treasury Bond ETF ($10.76 billion), Palo Alto Networks, Inc. ($9.37 billion), Strategy Inc ($7.58 billion), Invesco S&P 500 Equal Weight ETF ($6.78 billion), SPDR S&P Biotech ETF ($6.72 billion), AppLovin Corporation ($6.37 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($6.29 billion). View all of the most shorted stocks.

Short selling JUNS is an investing strategy that aims to generate trading profit from Jupiter Neurosciences as its price is falling. JUNS shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Jupiter Neurosciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of JUNS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including JUNS, twice per month. The most recent reporting period available is August, 31 2025.